Clinical Trial Update: Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

View source ↗

Summary

Clinical trial update for intravesical N-803 plus BCG in BCG-naive non-muscle invasive bladder cancer, with the study listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• N-803

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Non Muscle Invasive Bladder Cancer | Status: ACTIVE_NOT_RECRUITING